News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Isotechnika Pharma Inc. (ISA.TO)'s NICAM Compounds Demonstrate Positive Anti-Hepatitis C Virus Activity in Secondary Level Testing at National Institutes of Health (NIH)-Funded Labs



12/7/2012 9:42:04 AM

EDMONTON, Alberta, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") is pleased to announce positive anti-hepatitis C virus ("HCV") results from the second round of in vitro testing of its cyclophilin antagonist molecules ("NICAMs"). Contractors funded by the National Institute of Allergy and Infectious Diseases ("NIAID"), part of the U.S. National Institutes of Health ("NIH"), carried out the testing.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES